Yes—adding orforglipron, a daily diabetes pill, to insulin lowered blood sugar more than insulin with a dummy pill over 40 weeks. The study followed 546 adults with type 2 diabetes in five countries. Their blood sugar remained above target while taking insulin glargine, a long-acting insulin. Researchers assigned people by chance to three pill doses or a dummy pill. Everyone continued insulin, with doses adjusted during the study. The main measure was HbA1c (Hemoglobin A1c), which reflects average blood sugar over about three months. The average starting result was 8.50%. After 40 weeks, results fell by 1.58 percentage points with 3 mg daily. They fell by 1.88 points with 12 mg and 1.82 points with 36 mg. The dummy-pill group had a smaller drop of 0.79 points. Each dose beat the dummy pill. More people taking orforglipron also reached the study’s blood sugar targets. These were below 7.0% or at most 6.5%. Weight fell by an average of 2.6%, 4.8%, and 5.4% across the three doses. The dummy-pill group gained 0.2%. The most common side effects involved digestion and were mild to moderate. The study found no increased risk of dangerously low blood sugar compared with the dummy pill. For BioSocial members, these results offer context—not a prediction of anyone’s next result. This study tested an added pill, not a replacement for insulin. Comparing starting numbers, medication doses, and time between blood tests can make community notes more useful. Side effects belong in that picture, too. What changes have you seen in your bloodwork after a diabetes medication change, and over what time frame?